Seven Fleet Capital Management LP purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 35,286 shares of the company’s stock, valued at approximately $677,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Denali Therapeutics by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock valued at $1,210,000 after purchasing an additional 3,432 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Denali Therapeutics by 58.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after purchasing an additional 614,555 shares during the last quarter. Empowered Funds LLC raised its stake in shares of Denali Therapeutics by 11.0% during the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after purchasing an additional 2,052 shares during the last quarter. Woodline Partners LP lifted its holdings in shares of Denali Therapeutics by 13.5% during the first quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock worth $1,543,000 after purchasing an additional 13,517 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Denali Therapeutics by 1.7% during the second quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company’s stock worth $2,681,000 after purchasing an additional 3,210 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.
Denali Therapeutics Stock Down 5.5%
Denali Therapeutics stock opened at $23.02 on Friday. The stock’s 50 day moving average price is $23.12 and its 200 day moving average price is $21.07. Denali Therapeutics Inc. has a 1-year low of $12.58 and a 1-year high of $27.30. The company has a market cap of $3.65 billion, a PE ratio of -7.99 and a beta of 0.96. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28.
Wall Street Analysts Forecast Growth
DNLI has been the topic of several recent research reports. BTIG Research reissued a “buy” rating and issued a $39.00 price objective on shares of Denali Therapeutics in a research note on Monday, May 11th. JPMorgan Chase & Co. assumed coverage on shares of Denali Therapeutics in a research note on Monday, July 13th. They issued an “overweight” rating and a $29.00 target price for the company. Deutsche Bank Aktiengesellschaft raised their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Finally, Wedbush reiterated an “outperform” rating and set a $26.00 price target on shares of Denali Therapeutics in a research note on Monday, July 13th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $35.17.
Read Our Latest Stock Report on DNLI
Denali Therapeutics Profile
Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.
Read More
- Five stocks we like better than Denali Therapeutics
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report).
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
